On March 25 2026, DBV Technologies announced that it had been admitted to the CAC Mid 60 and SBF 120 indices, with the changes taking effect on March 23 2026. The Euronext Paris annual review, held on March 12 2026, determined that the company met the free‑float adjusted market‑capitalization and trading‑volume thresholds required for inclusion.
The CAC Mid 60 tracks the 60 most actively traded mid‑cap French companies that rank below the CAC Large 60, while the SBF 120 aggregates all companies in both the CAC Large 60 and CAC Mid 60. Inclusion in these indices signals that DBV’s market presence and liquidity meet the rigorous standards set by Euronext Paris, positioning the company among the most liquid mid‑cap stocks in France.
Being added to these widely followed indices is expected to raise DBV’s profile among European institutional investors and index‑tracking funds. The move should improve liquidity as ETFs and mutual funds that track the CAC Mid 60 and SBF 120 will need to purchase and hold the company’s shares, potentially easing trading and supporting a more efficient market for the stock.
The announcement comes at a pivotal moment for DBV’s core product, the Viaskin peanut patch. The company plans to submit a U.S. Food and Drug Administration application for children aged 4‑7 in the first half of 2026, following positive Phase 3 VITESSE trial results. A supplemental safety study for toddlers aged 1‑3 is underway, with an accelerated approval pathway in place and a BLA submission anticipated in the second half of 2026. The index inclusion therefore underscores the market’s recognition of DBV’s progress toward commercialization.
CEO Daniel Tassé said, "We are proud to be admitted into the CAC Mid 60 and SBF 120 Indices, which reflect the financial markets' recognition of our continued progress." He added, "We believe that inclusion in these widely followed indices will increase our visibility among the French and broader European investment communities as we prepare for commercialization and work to deliver meaningful innovation to the food allergy community."
Overall, the admission marks a significant corporate milestone that could enhance investor confidence, broaden the shareholder base, and support DBV’s future capital‑raising efforts as it moves closer to commercializing its Viaskin peanut patch.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.